Prospective audit of conversion from regular to lispro insulin during routine clinical care

Internal Medicine Journal

Volumn 34, Issue 6, 2004, Pages 320-323

  Lunt, H ^a   Kendall, D ^b   Moore, M P ^b   Scott, R S ^b   Cole, D ^b   Frampton, C M ^b   Cullens, M ^b  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b NONE

Author keywords

Body mass index; Diabetes mellitus; Glycaemic control; Hypoglycaemia; Insulin lispro

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; INSULIN LISPRO; ISOPHANE INSULIN; SHORT ACTING DRUG;

ANALYTIC METHOD; ARTICLE; BODY MASS; CONTROLLED STUDY; DRUG UTILIZATION; FEMALE; FOLLOW UP; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MEAL; MEDICAL AUDIT; MEDICAL CARE; PATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOLUBILITY;

BODY MASS INDEX; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; MEDICAL AUDIT; PROSPECTIVE STUDIES;

EID: 3242761434     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1444-0903.2004.00593.x     Document Type: Article

References (14)

1. Madsbad S. Insulin analogues: have they changed insulin treatment and improved glycaemic control? Diabetes Metab Res Rev 2002; 18 Suppl 1: S21-8.
2. Dunn CJ, Plosker GL. Insulin lispro: a pharmacoeconomic review of its use in diabetes mellitus. Pharmacoeconomics 2002; 20: 989-1025.
3. Stocks AE. Insulin lispro: experience in a private practice setting. Med J Aust 1999; 170: 364-7.
4. Chatterjee S, Gallen IW, Sandler L. 2-year prospective audit of the effect of the introduction of insulin lispro in patients with specific clinical indications. Diabetes Care 1999; 22: 1226-7.
5. Kong N, Kitchen MM, Ryder REJ. The use of lispro for high sugar content snacks between meals in intensive insulin regimens. Diabetic Med 2000; 17: 331-2.
6. Anderson JH Jr, Brunelle RL, Koivisto VA, Trautmann ME, Vignati L, Di Marchi R et al. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Clin Ther 1997; 19: 62-72.
7. Home PD, Lindholm A, Hylleberg B. Improved glycaemic control with insulin aspart. Diabetes Care 1998; 21: 1904-9.
8. Anderson JH Jr, Brunelle RL, Koivisto VA, Pfutzner A, Trautmann ME, Vignati L et al. Reduction of postprandial hyperglycaemia and frequency of hypoglycaemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes 1997; 46: 265-70.
9. Holleman F, Schmitt H, Rottiers R, Rees A, Symanowski S, Andeson JH. Reduced frequency of severe hypoglycaemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group. Diabetes Care 1997; 20: 1827-32.
10. Gale EA. A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy. The UK Trial Group. Diabet Med 2000; 17: 209-14.
11. Holcombe JH, Zalani S, Arora VK, Mast CJ. Lispro in Adolescents Study Group. Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents. Clin Ther 2002; 24: 629-38.
12. Home PD. Rapid-acting insulin analogues: when randomised clinical trial results do not help. Diabet Med 2000; 17 Suppl 2: 1-15.
13. Herman WH. Evidence-based diabetes care. Clin Diabetes 2002; 20: 22-3.
14. Stades AM, Hoekstra JB, van den Tweel I, Erkelens DW, Holleman F. STABILITY Study Group. Additional lunchtime basal insulin during insulin lispro intensive therapy in a randomized, multicenter, crossover study in adults: a real-life design. Diabetes Care 2002; 25: 712-17.